312 related articles for article (PubMed ID: 24342980)
1. Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction.
LaMattina JC; Jason MP; Hanish SI; Ottmann SE; Klassen DK; Potosky D; Hutson WR; Barth RN
Transplantation; 2014 Jan; 97(2):133-7. PubMed ID: 24342980
[TBL] [Abstract][Full Text] [Related]
2. Belatacept utilization recommendations: an expert position.
Grinyó JM; Budde K; Citterio F; Charpentier B
Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
[TBL] [Abstract][Full Text] [Related]
3. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
Martin ST; Tichy EM; Gabardi S
Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
[TBL] [Abstract][Full Text] [Related]
4. Biological agents in kidney transplantation: belatacept is entering the field.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
[TBL] [Abstract][Full Text] [Related]
5. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients.
Mitwalli AH; Alam A; Al-Wakeel J; Al Suwaida K; Tarif N; Schaar TA; Al Adbha B; Hammad D
Nephron Clin Pract; 2006; 102(2):c72-80. PubMed ID: 16244496
[TBL] [Abstract][Full Text] [Related]
6. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
[TBL] [Abstract][Full Text] [Related]
7. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Charlton M; Seaberg E
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S107-14. PubMed ID: 10431024
[TBL] [Abstract][Full Text] [Related]
8. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
Bajjoka I; Hsaiky L; Brown K; Abouljoud M
Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
[TBL] [Abstract][Full Text] [Related]
9. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
[TBL] [Abstract][Full Text] [Related]
10. Belatacept: a new biologic and its role in kidney transplantation.
Su VC; Harrison J; Rogers C; Ensom MH
Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
[TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.
Mulgaonkar S; Kaufman DB
Clin Transplant; 2014 Nov; 28(11):1209-24. PubMed ID: 25142257
[TBL] [Abstract][Full Text] [Related]
12. Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.
Arora S; Tangirala B; Osadchuk L; Sureshkumar KK
Expert Opin Biol Ther; 2012 Jul; 12(7):965-79. PubMed ID: 22564126
[TBL] [Abstract][Full Text] [Related]
13. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
14. Costimulation blockade with belatacept in renal transplantation.
Vincenti F; Larsen C; Durrbach A; Wekerle T; Nashan B; Blancho G; Lang P; Grinyo J; Halloran PF; Solez K; Hagerty D; Levy E; Zhou W; Natarajan K; Charpentier B;
N Engl J Med; 2005 Aug; 353(8):770-81. PubMed ID: 16120857
[TBL] [Abstract][Full Text] [Related]
15. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
Charpentier B
Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
17. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
Martin ST; Powell JT; Patel M; Tsapepas D
Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
[TBL] [Abstract][Full Text] [Related]
18. Belatacept-based, ATG-Fresenius-induction regimen for kidney transplant recipients: a proof-of-concept study.
Cicora F; Mos F; Petroni J; Casanova M; Reniero L; Roberti J
Transpl Immunol; 2015 Jan; 32(1):35-9. PubMed ID: 25448417
[TBL] [Abstract][Full Text] [Related]
19. Co-stimulatory blockade with belatacept in kidney transplantation.
Chopra B; Sureshkumar KK
Expert Opin Biol Ther; 2014 May; 14(5):563-7. PubMed ID: 24620724
[TBL] [Abstract][Full Text] [Related]
20. Belatacept for renal rescue in lung transplant patients.
Timofte I; Terrin M; Barr E; Sanchez P; Kim J; Reed R; Britt E; Ravichandran B; Rajagopal K; Griffith B; Pham S; Pierson RN; Iacono A
Transpl Int; 2016 Apr; 29(4):453-63. PubMed ID: 26678245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
